EHS
EHS

Long-Term Ocrelizumab Reduces Relapse Rate and Disability Progression in MS

Patients with multiple sclerosis who initiated ocrelizumab therapy earlier and continued long-term treatment sustained lower annualized relapse rates.

Source link

EHS
Back to top button